Tirzepatide Aqueous Formulation With Non-Inorganic Buffers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions of tirzepatide, a dual GLP-1 and GIP receptor agonist, face challenges such as chemical instability, aggregation, and immunogenicity due to the use of inorganic buffers like sodium phosphate, which can lead to precipitation, hydrolysis, and fibril formation, compromising stability and safety.
Innovation Solution
Formulating tirzepatide with non-inorganic buffers having a pKa of at least 6.6, such as zwitterionic buffers like HEPES or organic amine-based buffers like Tris, maintaining a pH between 6.5 to 8.5, and using nitrogen bubbling and refrigeration to minimize impurities and fibril formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Temperature
If inorganic buffers like sodium phosphate are used to control pH, then pH control is effective, but chemical stability deteriorates due to precipitation, hydrolysis, and deamidation
Solution Approach 1:
The patent changes the chemical composition parameter by replacing inorganic phosphate buffers with organic buffer systems (acetate, citrate, tartaric acid, or their combinations) that have different chemical properties. These organic buffers operate at pH 4.5-6.5, which prevents the chemical degradation pathways (precipitation, hydrolysis, deamidation) that occur with inorganic buffers, thereby improving chemical stability while maintaining pH control
Solution Approach 2:
The patent introduces organic acid intermediaries (acetate, citrate, tartaric acid) that mediate pH control without causing the harmful effects of inorganic phosphate buffers. These intermediaries buffer the pH through their own acid-base equilibria, preventing direct interaction between phosphate ions and the peptide that would lead to precipitation and hydrolysis
2Temperature
If inorganic buffers are used for pH control, then buffering capacity is maintained, but injection site irritation increases
Solution Approach 1:
The patent changes the chemical nature of the buffer from inorganic (sodium phosphate) to organic (acetate, citrate, tartaric acid), which fundamentally alters the interaction with biological tissues. Organic buffers are better tolerated at injection sites, reducing local irritation and inflammation while maintaining adequate buffering capacity at pH 4.5-6.5
3Temperature
If phosphate buffers are used, then pH stability is achieved, but crystallization occurs under storage conditions
Solution Approach 1:
The patent changes the buffer system from inorganic phosphate to organic acids (acetate, citrate, tartaric acid) that do not exhibit pH-dependent solubility issues leading to crystallization. These organic buffers remain soluble and stable across the storage temperature range while maintaining pH 4.5-6.5, preventing both crystallization and degradation of the peptide
4Temperature
If inorganic buffers are used, then buffering is effective, but calcium chelation leads to precipitate formation
Solution Approach 1:
The patent changes the buffer chemistry from inorganic phosphate to organic acids that have different metal ion binding properties. Acetate, citrate, and tartaric acid buffers do not strongly chelate calcium ions, preventing the formation of calcium phosphate precipitates that occur with inorganic phosphate buffers, while still providing effective pH buffering
5Stability of the object's composition
If heat treatment is applied to reduce fibril formation, then fibril dissolution is achieved, but energy consumption increases
Solution Approach 1:
The patent applies preliminary action by adjusting the pH to 4.5-6.5 using organic buffers before storage, which proactively prevents fibril formation from occurring in the first place. This preventive approach eliminates the need for subsequent heat treatment to dissolve fibrils, thereby reducing energy consumption while maintaining peptide stability
Solution Approach 2:
The patent converts the potential harm of low pH (which might be expected to increase degradation) into a benefit by selecting specific organic buffer systems that stabilize the peptide against fibril formation. The organic buffers at pH 4.5-6.5 create a chemical environment that prevents fibrillogenesis without requiring energy-intensive heat treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves improved chemical stability, reduced impurity content, and lower energy consumption, ensuring enhanced therapeutic efficacy and patient tolerability.
Implementation Method 1
The solution was transferred to a reaction vessel equipped with a nitrogen inlet and outlet, and the solution was sparged with nitrogen for 15 minutes to remove dissolved oxygen.
Implementation Method 2
The reaction vessel was placed in a refrigerator at 4°C overnight
Data Source
AI summary
The present invention relates to stable pharmaceutical compositions comprising tirzepatide, a dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. In particular, the invention provides aqueous formulations of tirzepatide containing non-inorganic buffering agents that improve chemical stability, bioavailability, and patient tolerability. The invention further encompasses pharmaceutical compositions formulated for enhanced storage stability and reduced aggregation, ensuring optimal therapeutic efficacy in the treatment of diabetes mellitus and obesity.